Business UpdateJul 29, 2026, 04:09 PM
Galmed Pharmaceuticals Terminates License Agreement with Yissum
AI Summary
Galmed Pharmaceuticals Ltd.'s wholly owned subsidiary, Galmed Research and Development Ltd., has mutually terminated a License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., effective July 31, 2026. As a result, all rights to the licensed technology will revert to Yissum, and Galmed will cease funding patent expenses and discontinue related activities. The company stated this decision was made to consolidate operations, reduce costs, and focus resources on the commercialization of Colospan and the continued development of Aramchol.
Key Highlights
- Galmed Pharmaceuticals' subsidiary terminated a License Agreement with Yissum Research Development Company.
- The termination is effective July 31, 2026.
- All rights to the licensed technology will revert to Yissum.
- Galmed's subsidiary will cease funding ongoing patent expenses related to the licensed patents.
- The company will discontinue all activities related to the licensed technology.
- Termination aims to consolidate operations, reduce costs, and focus resources.
- Galmed will focus on commercialization of Colospan and development of Aramchol.
Price Impact
More from GLMD